Is Kenvue (KVUE) a risky stock?
As of July 21, 2026, Clavix grades Kenvue (KVUE) C+ for risk, a composite score of 67 out of 100 on an A+ to F scale, which puts KVUE in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind KVUE's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how KVUE scores on each, as of July 21, 2026.
What's moving KVUE's risk right now
Company-specific signals Clavix flags behind KVUE's current grade, drawn from recent news and filings as of July 21, 2026.
The revival of these lawsuits creates ongoing legal uncertainty and potential financial liability for Kenvue, even though the underlying claims lack scientific support.
This campaign suggests Kenvue is investing in brand differentiation for Neutrogena within a competitive skincare market, potentially supporting brand equity and consumer trust, th…
While growth investors scrambled for cover in 2026, a quiet group of battle-tested income stocks started leaving the S&P 500 in the dust. Four Dividend Kings with decades of unbro…
What a C+ grade means
On the Clavix A+ to F scale, KVUE's composite of 67 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell KVUE or any security. Grades are risk indicators, not predictions of return. Data may be delayed.